KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCash from Discontinued OperationsCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TherapeuticsMD (TXMD) Change in Receivables (2016 - 2022)

TherapeuticsMD (TXMD) has disclosed Change in Receivables for 13 consecutive years, with -$13.6 million as the latest value for Q3 2022.

  • For the quarter ending Q3 2022, Change in Receivables fell 439.82% year-over-year to -$13.6 million, compared with a TTM value of -$4.3 million through Sep 2022, down 130.19%, and an annual FY2021 reading of $4.3 million, down 47.39% over the prior year.
  • Change in Receivables was -$13.6 million for Q3 2022 at TherapeuticsMD, down from $11.1 million in the prior quarter.
  • Across five years, Change in Receivables topped out at $11.1 million in Q2 2022 and bottomed at -$13.6 million in Q3 2022.
  • Average Change in Receivables over 5 years is $1.6 million, with a median of $790885.0 recorded in 2018.
  • The sharpest move saw Change in Receivables tumbled 2767.32% in 2018, then skyrocketed 48326.09% in 2022.
  • Year by year, Change in Receivables stood at -$1.8 million in 2018, then soared by 629.91% to $9.3 million in 2019, then fell by 7.4% to $8.6 million in 2020, then crashed by 114.32% to -$1.2 million in 2021, then tumbled by 1006.81% to -$13.6 million in 2022.
  • Business Quant data shows Change in Receivables for TXMD at -$13.6 million in Q3 2022, $11.1 million in Q2 2022, and -$489000.0 in Q1 2022.